Cellectar Reports Iopofosine I 131 Data in BTKi-Refractory Waldenström Macroglobulinemia
FLORHAM PARK, N.J. — September 29, 2026 Cellectar Biosciences announced that a subset analysis from the Phase 2 CLOVER-WaM...
PDC
Advertisement
Avacta Achieves Clinical Proof of Mechanism for AVA6103
LONDON and PHILADELPHIA — September 16, 2026 Avacta Therapeutics announced clinical proof of mechanism for AVA6103, its next-generation controlled-release...
TwoStep Therapeutics Secures $62.5M and FDA IND Clearance
SAN CARLOS, Calif. — September 9, 2026 TwoStep Therapeutics announced an oversubscribed $62.5 million Series A financing alongside U.S....
Advertisement
